Mrna 1273 spikevax

Manufactured by Moderna

MRNA-1273/Spikevax is a vaccine product developed by Moderna. It is a messenger RNA (mRNA) vaccine that provides instructions for human cells to produce a harmless piece of the SARS-CoV-2 spike protein, which then triggers an immune response. The core function of this product is to generate an immune response against the SARS-CoV-2 virus.

Automatically generated - may contain errors

Lab products found in correlation

Bnt162b2 comirnaty, by Pfizer (2 mentions) Azd1222 vaxzevria, by AstraZeneca (2 mentions)

2 protocols using mrna 1273 spikevax

Longitudinal SARS-CoV-2 Antibody Dynamics in Milk

Check if the same lab product or an alternative is used in the 5 most similar protocols

This prospective longitudinal cohort study is a follow-up study of the COVID MILK – POWER MILK study.³⁴ (link) All samples were subjected to longitudinal analysis of specific antibodies against SARS-CoV-2 in human milk and serum after vaccination against COVID-19 with either BNT162b2/Comirnaty developed by Pfizer-BioNTech, mRNA-1273/Spikevax developed by Moderna, AZD1222/Vaxzevria developed by Oxford/AstraZeneca and Ad26.COV2.S developed by J&J/Janssen. Ethical approval was acquired from the Independent Ethics Committee of the Vrije Universiteit Medical Center (2020.425/NL74752.029.20). The study was conducted in accordance with the principles of the declaration of Helsinki and the ICH GCP Guidelines, and the Regulation on Medical Research involving Human subjects and reported in adherence to the CONSORT reporting guidelines.

Juncker H.G., Mulleners S.J., Ruhé E.J., Coenen E.R., Bakker S., van Doesburg M., Harinck J.E., Rood R.D., Bouhuijs J.H., Oomen M., de Groot P.C., Pajkrt P.D., Korosi A., van Goudoever P.J., van Gils M.J, & van Keulen B.J. (2022). Comparing the human milk antibody response after vaccination with four COVID-19 vaccines: A prospective, longitudinal cohort study in the Netherlands. eClinicalMedicine, 47, 101393.

+ Open protocol

+ Expand

COVID-19 Vaccination Antibody Response in Breast Milk

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

In this observational longitudinal case series we used samples from an existing prospective longitudinal study COVID MILK – POWER MILK (28 (link)). All participants were subjected to longitudinal analysis of specific antibodies against the SARS-CoV-2 spike-protein by ELISA and general SIgA1 Fab clonal profiling in human milk after vaccination against COVID-19 with BNT162b2/Comirnaty developed by Pfizer-BioNTech, mRNA-1273/Spikevax developed by Moderna or AZD1222/Vaxzevria developed by Oxford/AstraZeneca. Ethical approval was acquired from an Independent Ethics Committee (2020.425/NL74752.029.20). The study was conducted in accordance with the principles of the declaration of Helsinki and the ICH GCP Guidelines, and the Regulation on Medical Research involving Human subjects.

de Graaf S.C., Bondt A., van Rijswijck D.M., Juncker H.G., Mulleners S.J., Damen M.J., Hoek M., van Keulen B.J., van Goudoever J.B., Heck A.J, & Dingess K.A. (2024). A case series exploring the human milk polyclonal IgA1 response to repeated SARS-CoV-2 vaccinations by LC–MS based fab profiling. Frontiers in Nutrition, 10, 1305086.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!